Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wisconsin Technology Today.
Press releases published on July 8, 2025
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
GlobeNewswire
·
July 8, 2025
HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, …
Sanborn Geophysics Doubles Production, Launches Upgraded Product Line, and Prepares Move to Purpose-Built Facility
GlobeNewswire
·
July 8, 2025
COLORADO SPRINGS, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Sanborn Geophysics ULC, a subsidiary of The Sanborn Map Company, today announced a major step in its evolution from general geophysical solutions to a product-driven model capable of meeting …
Calian Reinforces Support for Canadian Armed Forces with $250M Contract Amendment
GlobeNewswire
·
July 8, 2025
OTTAWA, Ontario, July 08, 2025 (GLOBE NEWSWIRE) -- Calian Group Ltd. (TSX: CGY), a mission-critical solutions company focused on defence, space, healthcare and other strategic critical infrastructure sectors, today announced a $250 million amendment to its …
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
GlobeNewswire
·
July 8, 2025
Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the …
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia
GlobeNewswire
·
July 8, 2025
Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations as a novel surrogate endpoint for Larimar’s planned BLA submission in Q2 2026 seeking accelerated approval BALA CYNWYD, …
Xtract One Selected by Mecklenburg County Public Schools to Enhance Building Security District-Wide
GlobeNewswire
·
July 8, 2025
TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced its Xtract One Gateway (“Gateway”) system has been selected by Mecklenburg County Public Schools, located …
Mercury Receives Two New Common Processing Architecture Production Awards
GlobeNewswire
·
July 8, 2025
ANDOVER, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a technology company that delivers mission-critical processing to the edge, today announced it received two new production awards in June totaling $36.9 …
CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025
GlobeNewswire
·
July 8, 2025
BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual and in-person …
Agios Appoints Dr. Jay Backstrom to Board of Directors
GlobeNewswire
·
July 8, 2025
CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the appointment of Jay Backstrom, M. …
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
GlobeNewswire
·
July 8, 2025
Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week as a late-breaking clinical trial In Group 1 (n=24), kidney function stabilized in patients randomized to receive two rilparencel …
ROM: Golden Age Blasts Past 500,000 Pre-Registrations - Join the Buddy Boost Lottery for a Shot at Massive Crypto Prizes
GlobeNewswire
·
July 8, 2025
Singapore, July 08, 2025 (GLOBE NEWSWIRE) -- Big news: ROM: GoldenAge—the hottest upcoming blockchain strategy game—has just smashed through half a million pre-registrations on WEMIX PLAY! Yes, over 500,000 pre-registrations! Pre-register now and …
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
GlobeNewswire
·
July 8, 2025
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for verekitug into third indication, strengthening pipeline …
Jade Biosciences to Participate in Two Upcoming Investor Conferences
GlobeNewswire
·
July 8, 2025
SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its …
Energous Reports Preliminary Record Quarterly Revenue, Achieves Lowest Net Loss in Ten Years, and Retires High-Interest Debt
GlobeNewswire
·
July 8, 2025
SAN JOSE, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Energous Corporation d/b/a Energous Wireless Power Solutions (NASDAQ: WATT), a leader in over-the-air (OTA) wireless power networks, today announced preliminary results for its second quarter of 2025, …
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
GlobeNewswire
·
July 8, 2025
Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study to a Phase 2b placebo-controlled study. This is a critical step required prior to proceeding to pivotal clinical trials necessary …
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
GlobeNewswire
·
July 8, 2025
- NDA assigned a Target Action Date of February 25, 2026 - - Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical …
RentRedi CEO Ryan Barone Named to Inman’s 2025 Future Leaders in Real Estate List
GlobeNewswire
·
July 8, 2025
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- RentRedi, the fastest-growing landlord software that makes renting easy for everyone, has announced that its Co-founder and CEO Ryan Barone was named to Inman’s Future Leaders in Real Estate list in the …
Castellum and AmpliTech Group Announce Execution of Reseller Agreement
GlobeNewswire
·
July 8, 2025
VIENNA, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-American: CTM) (the “Company” and “Castellum”) and AmpliTech Group, Inc. (Nasdaq: AMPG) (“AmpliTech”) are pleased to jointly announce that the Company’s newly formed product subsidiary, …
DIMO and Ownli Partner to Bring Data Ownership and Insurance Savings to Connected Drivers
GlobeNewswire
·
July 8, 2025
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- DIMO, the leading connected vehicle platform, today announced a partnership with Ownli, the platform that helps people collect, certify, and earn from their vehicle and driving data. Together, DIMO and Ownli are …
VertiGIS Unveils Industry-Focused AI-Powered Cloud Solutions to Transform Spatial Asset Management and Drive Productivity
GlobeNewswire
·
July 8, 2025
VertiGIS Neo drives efficiency and flexibility across multiple sectors with its industry focused solutions London, UK. 8th July, 2025 – VertiGIS, a leading global provider of spatial asset management solutions, today unveiled a new, secure cloud-based …